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Abstract
In morphine tolerance a key question that remains to be answered is whether l-opioid receptor (MOPr) desensitization contributes to
morphine tolerance, and if so by what cellular mechanisms. Here we demonstrate that MOPr desensitization can be observed in
single rat brainstem locus coeruleus (LC) neurons following either prolonged (> 4 h) exposure to morphine in vitro or following
treatment of animals with morphine in vivo for 3 days. Analysis of receptor function by an operational model indicated that with either
treatment morphine could induce a profound degree (70–80%) of loss of receptor function. Ongoing PKC activity in the MOPr-
expressing neurons themselves, primarily by PKCa, was required to maintain morphine-induced MOPr desensitization, because
exposure to PKC inhibitors for only the last 30–50 min of exposure to morphine reduced the MOPr desensitization that was induced
both in vitro and in vivo. The presence of morphine was also required for maintenance of desensitization, as washout of morphine for
> 2 h reversed MOPr desensitization. MOPr desensitization was homologous, as there was no change in a2-adrenoceptor or ORL1
receptor function. These results demonstrate that prolonged morphine treatment induces extensive homologous desensitization of
MOPrs in mature neurons, that this desensitization has a signiﬁcant PKC-dependent component and that this desensitization
underlies the maintenance of morphine tolerance.
Introduction
The analgesic, respiratory depressant and rewarding effects of
morphine occur through activation of l-opioid receptors (MOPrs;
Matthes et al., 1996; Romberg et al., 2003). Tolerance to these in vivo
responses develops on prolonged exposure (Roerig et al., 1987;
Shippenberg et al., 1989; Smith et al., 1999). For many G-protein-
coupled receptors prolonged exposure to an agonist results in rapid
receptor desensitization through a variety of mechanisms that may
involve speciﬁc kinases (GRKs) or second messenger kinases, such as
protein kinase C (PKC) and A (Kelly et al., 2008). Initial studies
suggested that morphine does not induce MOPr desensitization in
mature neurons (Alvarez et al., 2002), leading to the suggestion that
receptor desensitization was not involved in morphine tolerance (Finn
& Whistler, 2001). More recently, however, morphine-induced MOPr
desensitization has been observed in mature neurons (Bailey et al.,
2003, 2004; Dang & Williams, 2005; Virk & Williams, 2008),
although the extent of the desensitization is less than that observed
with other opioids.
Our work studying acute MOPr desensitization of recombinant
MOPrs and endogenous MOPrs in mature brain neurons has revealed
a PKC-dependent component of morphine-induced MOPr desensiti-
zation (Bailey et al., 2004, 2006; Johnson et al., 2006), whereas for
the opioid peptide, DAMGO, desensitization was almost entirely
through a GRK-dependent mechanism (Johnson et al., 2006). There is
also evidence to suggest that in vivo different opioids induce tolerance
by different mechanisms. In GRK3 knockout mice the antinociceptive
tolerance that develops to fentanyl was markedly reduced, but that
which develops to morphine was not (Terman et al., 2004). A number
of studies have reported that PKC is involved in morphine-induced
tolerance in vivo (Inoue & Ueda, 2000; Zeitz et al., 2001; Bohn et al.,
2002; Hua et al., 2002; Smith et al., 2003, 2007). However, such
in vivo studies do not delineate where in the sequence of intracellular
events PKC acts to induce such tolerance.
In this study we have determined the role PKC-induced MOPr
desensitization plays in the tolerance to morphine that develops in
mature neurons on prolonged exposure to the drug in vitro and in vivo.
To do this we have developed a protocol with which the level of MOPr
desensitization can be determined in adult mammalian neurons in the
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European Journal of Neurosciencecontinued presence of the drug. This approach has allowed us to study
the time-course of development of MOPr desensitization at the single
cell level in brain slices exposed to morphine in vitro, and to compare
the MOPr desensitization observed in vitro with that observed in brain
slices prepared from animals chronically treated with morphine (i.e.
ex vivo). We found that with both in vitro and in vivo morphine pre-
treatment the major component of MOPr desensitization requires
ongoing PKC activity to be maintained, whereas incubation of slices
with DAMGO induced MOPr desensitization that was not PKC
dependent. Analysis of the data using an operational model of drug
agonism has allowed us to assess and compare the actual loss of MOPr




Male Wistar rats (130–170 g) were killed by cervical dislocation, and
horizontal brain slices (200–250 lm thick) containing the locus
coeruleus (LC) were prepared as described (Bailey et al., 2003). All
experiments were performed in accordance with the UK Animals
(Scientiﬁc Procedures) Act 1986, the European Communities Council
Directive 1986 (86⁄609⁄EEC) and the University of Bristol ethical
review document.
Whole-cell patch-clamp recordings
Slices were submerged in a slice chamber (0.5 mL) mounted on the
microscope stage and superfused (2.5–3 mL⁄min) with artiﬁcial
cerebrospinal ﬂuid (aCSF) composed of (in mm): NaCl, 126; KCl,
2.5; MgCl2, 1.2; CaCl2, 2.4; NaH2PO4, 1.2; d-glucose, 11.1; NaHCO3,
21.4; ascorbic acid, 0.1; saturated with 95% O2⁄5% CO2 at 33–34 C.
For patch-clamp recording LC neurons were visualized by Nomarski
optics using infrared light and individual cell somata were cleaned by
gentle ﬂow of aCSF from a pipette. Whole-cell voltage-clamp
recordings (Vh = )60 mV) were made using electrodes (3–6 MX)
ﬁlledwith(inmm):K-gluconate,115;HEPES,10;EGTA,11;MgCl2,2;
NaCl, 10; MgATP, 2; Na2GTP, 0.25 (pH 7.3, osmolarity 270 mOsm).
Recordings of whole-cell current were ﬁltered at 2 kHz using an
Axopatch 200B ampliﬁer and analysed off-line using pClamp.
Activation of MOPrs evoked a transmembrane K
+ current, and by
performing whole-cell patch-clamp recordings a real-time index of
MOPr activation could be continually recorded. The opioid-evoked
current was continuously recorded at a holding potential of )60 mV.
MOPrsanda2-adrenoceptorscoupletothesamesetofK
+channelsinLC
neurons (North & Williams, 1985). To reduce variation between cells,
the amplitudes of all opioid-evoked currents were normalized to the
maximum current evoked by noradrenaline (NA; 100 lm) in the same
cell.NAresponseswereunchangedbyanyofthedrugtreatmentsusedin
this study. Therefore, any desensitization of MOPrs observed must be
homologoustotheMOPr.ToensurethatresponsestoNAweremediated
through a2-adrenoceptors and not attenuated by uptake, NAwas always
applied in the presence of prazosin (1 lm) and cocaine (3 lm).
All drugs were applied in the superfusing solution at known
concentrations. Drugs and chemicals used were from Sigma
(Gillingham, UK), except Met-Enkephalin (Bachem, Bubendorf,
Switzerland) and Go6976 (Tocris, Bristol, UK). RACK inhibitors
were from Kai Pharmaceuticals, San Francisco, CA, USA. The
speciﬁc RACK inhibitors used were KIG31-1 (a PKCc inhibitor),
KIBI31-1 (a PKCbI inhibitor), KIBII31-1 (a PKCbII inhibitor) and
KIC1-1 (a classical PKC isoform inhibitor).
Induction of morphine tolerance
In vitro
Slices were placed on a nylon mesh platform in a pre-incubation
chamber containing approximately 250 mL of aCSF at 33–34 C.
Given adequate oxygenation, slices incubated in this manner remained
viable for up to 12 h. To induce morphine tolerance, morphine (1 or
30 lm) was added to the aCSF bathing the slices for periods of up to
6 h prior to mounting the slices in the recording chamber. The aCSF
bathing the slices in the recording chamber also contained morphine at
the same concentration as used in the pre-incubation treatment.
Whole-cell recordings were then obtained and the slices challenged
with opioids up to 9 h after the start of the morphine treatment.
In vivo
To induce morphine tolerance rats were injected subcutaneously with
200 mg⁄kg morphine base contained in a slow-release formulation
that contained 200 mg⁄mL morphine base suspended in an emulsion
containing 0.9% NaCl, liquid parafﬁn oil and mannide monooleate
(Arlacel A) in a ratio of 0.5 : 0.42 : 0.08 (v : v : v). Three days after
injection of the slow-release morphine the animals were killed and
brain slices prepared as described above. This method of morphine
treatment has previously been shown to induce signiﬁcant tolerance to




For statistical analysis, data are presented as mean ± standard error of
the mean, and an unpaired Student’s t-test was used to assess
signiﬁcance.
Operational model of agonism and loss of receptor function
The operational model of antagonism (Black et al., 1985) states that
E ¼ Emsn½A 
n=ðKa þ½ A Þ
n þ sn½A 
n ð1Þ
where the response E is expressed in terms of the concentration of
agonist A, the theoretical maximal effect Em (greater than that which
can be functionally attained; Black et al., 1985), the dissociation
constant Ka, the transducer ratio s and n is the slope of the curve (NB
n in this equation is not the Hill slope as suggested in Graph Pad
Prism). Em and n are intrinsic properties of the receptor⁄cell and are
independent of the agonist used, whereas s depends on the cell,
receptor function and agonist used. For the MOPrs in LC neurons,
values of Em and n were determined by constructing concentration–
response curves to Met-Enkephalin in the absence and presence of the
irreversible antagonist b-funaltrexamine (b-FNA; 30 nm for 30 min),
and subjecting the curves to simultaneous non-linear regression
analysis (see Fig. 5A). Having obtained values for Em and n in this
way, then the values of s and Ka were calculated for each agonist by
ﬁtting concentration–response curves by non-linear regression.
Following treatments that result in MOPr desensitization, the value
of s, which is dependent on the efﬁcacy of agonist–receptor coupling
and the number of functional receptors, would be reduced. Therefore,
to determine the loss of receptor function resulting from prolonged
agonist treatment we measured the response to morphine (30 lm; E2)
after the induction of desensitization. As Em and n are constants, and
assuming Ka to be unchanged, changes in E (from E to E2) must
therefore depend upon a change in transducer ratio value (from s to
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calculated (Lohse et al., 1990) using Eq. (2) below.
Results
Measuring MOPr desensitization following prolonged drug
exposure
To determine the extent of MOPr desensitization resulting from
prolonged morphine exposure, we developed a protocol that would
enable us to assess the extent of receptor desensitization following
prolonged morphine exposure without washing out the morphine as
washout of morphine would induce withdrawal and initiate reversal of
any desensitization that had been induced. To do this we made use of
the fact that morphine is a partial agonist at MOPrs in LC neurons
having a lower maximum response than other opioids such as Met-
Enkephalin and DAMGO (Fig. 1A and B; see also Alvarez et al.,
2002; Bailey et al., 2003). A basic tenet of receptor theory is that for a
partial agonist the maximum response is produced only when all of the
available receptors are occupied, and therefore any loss of MOPr
function as would occur if receptors were desensitized would result in
a decrease in the maximum response to the partial agonist. Therefore,
any deﬁcit in receptor function caused by drug treatments would be
seen as a decrease in the maximum response to morphine (measured
by applying a receptor-saturating concentration, 30 lm, of morphine).
In preliminary experiments on drug-naı ¨ve slices we demonstrated
that a receptor-saturating concentration of morphine (30 lm) evoked a
K
+ current that was 94 ± 13% of the maximum response evoked by
NA in the same neurons (Fig. 1B). In all our experiments the opioid
responses have been normalized to the maximum NA response (NA;
100 lm) mediated through a2-adrenoceptors in the same neuron to
control for variations in current amplitudes between neurons. MOPrs
and a2-adrenoceptors couple to the same set of GIRK channels in LC
neurons (North & Williams, 1985). Following washout of the
morphine for 3 min, application of a receptor-saturating concentration
of the full agonist, DAMGO (10 lm), evoked a response of
149 ± 15% of the maximum response to NA. These values for the
maximum responses evoked by morphine and DAMGO administered
sequentially to the same neurons are not different from those in slices
where neurons were exposed to only one of the opioids. This
demonstrates that it is possible in the same neuron to obtain maximum
response amplitudes for morphine and DAMGO.
MOPr desensitization following prolonged exposure to
morphine in vitro
Slices containing the LC were incubated for 6–9 h in 1 or 30 lm
morphine or control aCSF, and whole-cell patch-clamp recordings
were performed under the same conditions. Morphine (1 lm) was
chosen as it is a sub-maximal concentration of morphine, and has been
shown previously to approximate to the concentration measured in rat
brains following a moderate analgesic dose of morphine (Patrick et al.,
1978). Morphine (30 lm) was chosen as it is a receptor-saturating
concentration of morphine. The degree of MOPr desensitization
induced by each concentration of morphine was then assessed.
Figure 1C and D shows sample traces from LC neurons in slices
that had been incubated for 6–9 h in 1 lm or 30 lm morphine, and
then maintained in the continued presence of morphine whilst the
recording was initiated. Morphine (30 lm) and DAMGO (10 lm)
were then applied sequentially to obtain the maximum responses to
each drug, and naloxone (1 lm) applied to return the holding current
to the true baseline level from which opioid-evoked current amplitudes
could be measured. Pooled data (Fig. 1E) show that 6–9 h pre-
incubation in 1 lm morphine alone caused no statistically signiﬁcant
decrease in the maximum response to morphine, compared with data
from slices incubated in control aCSF for 6–9 h. In contrast, when LC
slices were incubated with 30 lm morphine for periods up to 6–9 h
there was a gradual decrease in the maximum response to morphine
over time that ﬁrst became statistically signiﬁcant at the 4–6 h time-
point (Fig. 1E); after 6–9 h pre-incubation the maximum response to
morphine had decreased by 63 ± 7%. Note, unlike rapid MOPr
desensitization (Bailey et al., 2004), that produced by prolonged
exposure to 30 lm morphine was observed without the need to
activate PKC with oxotremorine-M (oxo-M) or phorbol 12-myristate
13-acetate (PMA). To ensure that the desensitization induced by the
prolonged exposure to 30 lm morphine had not in some non-speciﬁc
way interfered with G-protein coupling or potassium channel function,
we also measured the amplitude of the maximum NA-evoked current.
There was no change in the amplitude of the maximum NA-evoked
current following exposure of LC slices to either 1 or 30 lm morphine
for up to 9 h (Fig. 1F and Supporting Information Fig. S1, A). It is
concluded therefore that exposure of LC neurons in vitro to 30 lm but
not 1 lm morphine, alone for 6–9 h, induces signiﬁcant homologous
MOPr desensitization.
Because 1 lm morphine alone did not induce MOPr desensitiza-
tion, we next examined the effect of PKC activation on the
development of MOPr desensitization during prolonged exposure to
1 lm morphine. Slices were incubated for 6–9 h with morphine
(1 lm) as well as oxo-M (10 lm) to activate PKC. In control
experiments 6–9 h incubation with oxo-M alone had no effect on the
maximum response to morphine, whereas following exposure to
morphine plus oxo-M the maximum response to morphine was
decreased to 46 ± 8% (Fig. 2A and B). The effect of oxo-M could be
mimicked by activating PKC with the phorbol ester, PMA. When
slices were incubated with both morphine (1 lm) and PMA (1 lm),
the maximum response to morphine was reduced by 52 ± 10%
(Fig. 2B). Like oxo-M, PMA alone (6–9 h) had no effect. Thus, MOPr
desensitization can be induced by prolonged exposure to 1 lm
morphine in vitro, but only when the PKC activity in LC neurons is
enhanced above the basal level in isolated neurons. The decrease in
responsiveness was selective to the MOPr, as the NA responses were
unaffected by any pre-treatment (Supporting Information Fig. S1, C).
In acute exposure (7 min) experiments, 1 lm morphine did not induce
MOPr desensitization in the absence or presence of PKC activation by
PMA (Fig. 2C), indicating that, even when PKC is activated, 1 lm
morphine causes MOPr desensitization only after prolonged exposure
to the drug.
Whilst prolonged exposure to morphine 30 lm alone, or morphine
1 lm + oxo-M or PMA, reduced the maximum response to morphine
and thus revealed a loss of functional MOPrs, only 30 lm morphine
pre-treatment resulted in a decrease in the maximum response to the
full agonist DAMGO (Supporting Information Fig. S1, B and D). As a
high-efﬁcacy agonist, DAMGO has a signiﬁcant spare receptor reserve
in LC neurons (Osborne & Williams, 1995), such that, in comparison
to the partial agonist morphine, a greater amount of MOPr desensi-
tization is required to produce a decrease in the maximum DAMGO
response.
Role of PKC in maintaining MOPr desensitization during
prolonged in vitro exposure to morphine
To examine whether ongoing PKC activity was required to maintain
MOPr desensitization, we investigated whether PKC inhibitors could
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European Journal of Neuroscience, 29, 307–318Fig. 1. Prolonged exposure to morphine in vitro results in MOPr desensitization. (A) Concentration–response curve for morphine in rat LC neurons. Morphine
responses were normalized to the maximum possible opioid response in each neuron, evoked by a brief (1 min), application of 10 lm Met-Enkephalin (Met-Enk;
n = 4; error bars represent SEM). (B) Sample current recording from an untreated LC neuron: a receptor-saturating concentration of morphine (30 lm; morph) was
applied, followed after 3-min wash by a receptor-saturating concentration of DAMGO (10 lm). The maximum response to morphine was less than that of DAMGO.
Following application of the MOPr antagonist naloxone (nalox; 1 lm), a receptor-saturating concentration of noradrenaline (NA; 100 lm) was applied. Scale bars:
50 pA and 5 min. (C) Example recording from an LC neuron, following 6–9 h pre-incubation with 1 lm morphine. Opioid-evoked and NA-evoked currents were
elicited using the protocol in (B), by applying 30 lm morphine without washing out the 1 lm morphine in which the slice had been incubated. Naloxone was applied
to reveal the baseline current level (dotted line). (D) Example recording following 6–9 h pre-incubation with 30 lm morphine. Note that compared with the NA
response, the maximum possible morphine and DAMGO responses were reduced (cf. current traces in B and C). (E) Prolonged treatment with 30 lm, but not 1 lm,
morphine reduced MOPr responsiveness as assessed by the maximum response to 30 lm morphine. The effect of 30 lm morphine was time dependent. Pooled data
from experiments as described in (C) and (D), displaying responses to 30 lm morphine, normalized to the maximum NA response (*P < 0.05 vs. control, Student’s
t-test; n = 3–6; error bars represent SEM). (F) Responses to NA following pre-incubation with 1 or 30 lm morphine were unchanged (n = 3–6; error bars represent
SEM).
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European Journal of Neuroscience, 29, 307–318Fig. 2. Prolonged exposure to morphine (1 lm) in vitro causes MOPr desensitization only when protein kinase C (PKC) is activated. (A) Sample current recording
from an LC neuron incubated for > 6 h with 1 lm morphine (morph) plus 10 lm oxotremorine-M (oxo-M) followed by the drug protocol described in Fig. 3 (scale
bars: 50 pA and 5 min). Naloxone (nalox) was applied to reveal the baseline current level (dotted line). (B) Following 6–9 h pre-incubation with 1 lm morphine
alone, there was no decrease in the response to morphine (30 lm) shown as a percentage of the maximum noradrenaline (NA) response. However, when LC neurons
were pre-treated with 1 lm morphine and either 10 lm oxo-M or 1 lm phorbol 12-myristate 13-acetate (PMA), the maximum morphine response was signiﬁcantly
decreased (*P < 0.05, Student’s t-test vs. control;
P < 0.05, Student’s t-test vs. 1 lm morphine alone). Six–nine hours pre-incubation with oxo-M or PMA alone
had no effect on opioid responses (n = 3–6; error bars represent SEM). (C) Morphine (1 lm) in the presence of 1 lm PMA did not induce rapid MOPr
desensitization. Black squares: 1 lm morphine + 1 lm PMA. Open circles: 30 lm morphine + 1 lm PMA. Error bars represent SEM.
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had already been induced. Slices were ﬁrst incubated with 1 lm
morphine + 10 lm oxo-M for 6–9 h, and then the conventional PKC
isoform inhibitor Go6976 (1 lm) was added for 15–30 min prior to
initiation of whole-cell recording, and for a further 15–20 min prior to
determining the maximum responses to morphine (i.e. the neurons
were only exposed to the PKC inhibitor for the last 30–50 min of the
6–9-h prolonged morphine exposure). Figure 3A and B shows that the
presence of Go6976 for the ﬁnal 30–50 min of incubation with
morphine + -M signiﬁcantly reversed the MOPr desensitization
induced by morphine. Go6976 alone had no effect on the maximum
response to morphine (Fig. 3B).
Having shown that MOPr desensitization to 1 lm morphine
required PKC activation, we next tested the hypothesis that the
desensitization induced by 30 lm morphine alone was because there
was sufﬁcient basal PKC activity to cause MOPr desensitization by
this receptor-saturating concentration of morphine. We incubated
slices with 30 lm morphine for 6–9 h, followed by addition of
Go6976 (1 lm) in the continued presence of morphine for 30–50 min
(i.e. prior to and during the recording period). Go6976 signiﬁcantly
reversed the tolerance induced by 30 lm morphine alone (Fig. 3B).
We next examined which PKC isoform(s) could be involved in the
MOPr desensitization induced by prolonged exposure (6–9 h) to
30 lm morphine alone using RACK inhibitors (Chen et al., 2001). We
ﬁrst used a RACK inhibitor that blocks all conventional PKC isoforms
(i.e. PKCa, bI, bII and c), but does not block novel (i.e. PKCd, e, h
and l) or atypical PKC isoforms (i.e. PKCn and k). Exposure of slices
to a RACK inhibitor that blocks all conventional PKC isoforms (i.e.
PKCa, bI, bII and c; Ron et al., 1995) for 30–50 min at the end of the
prolonged exposure to morphine signiﬁcantly reversed the MOPr
desensitization induced by 30 lm morphine (similar to when
conventional PKC isoforms were inhibited by Go6976), whereas
a combination of RACK inhibitors that block PKCbI, bII and
c (Johnson et al., 1996; Stebbins & Mochly-Rosen, 2001) did
not (Fig. 3C). These data indicate that PKCa is probably the
isoform required to maintain prolonged morphine-induced MOPr
desensitization.
For both 1 lm morphine + oxo-M and 30 lm morphine alone, the
MOPr desensitization was reversed when the PKC inhibitors were
added after 6–9 h of morphine exposure had already occurred and thus
MOPr desensitization had already been initiated. This demonstrates
that ongoing PKC activity is essential to maintain MOPr desensiti-
zation.
Role of PKC in maintaining MOPr desensitization following
in vivo exposure to morphine
Slices were prepared from rats pre-treated in vivo with morphine for
3 days (see Materials and methods). During all stages of slice
preparation the ﬂuid bathing the brain contained morphine (1 lm). In
LC neurons from morphine-pre-treated rats the maximum response to
morphine (30 lm) was signiﬁcantly lower than that observed in
parallel experiments on LC slices from untreated animals and not
incubated in morphine (Fig. 3D). In neurons from morphine-pre-
treated animals the maximum response to morphine was decreased by
48%. In these slices the maximum response to NA (156 ± 15 pA) was
not signiﬁcantly different from the maximum NA response evoked in
slices from non-morphine-pre-treated animals (Supporting Informa-
tion Fig. S1, A), suggesting that the MOPr tolerance observed was
homologous. To test this further, we examined whether chronic
morphine treatment caused ORL1 desensitization, a receptor that has
been shown to desensitize in a PKC-dependent manner (Pu et al.,
1999). We saw no effect on ORL1 function following in vivo
morphine treatment, further suggesting that the MOPr desensitization
was homologous (Fig. 3E).
To examine whether ongoing PKC activity was required to maintain
the MOPr desensitization induced by in vivo exposure to morphine,
slices were prepared as above and incubated in morphine (1 lm).
Whole-cell recordings were obtained and the conventional PKC
isoform inhibitor Go6976 (1 lm) was added for 30 min prior to
determining the maximum response to morphine. The presence of
Go6976 signiﬁcantly, but not completely, reversed the MOPr desen-
sitization induced by the in vivo morphine pre-treatment (Fig. 3D). As
well as ongoing PKC being required to maintain MOPr desensitiza-
tion, the MOPr needs to be bound by morphine. When morphine was
removed from the slice-bathing solution for 2–4 h, chronic morphine-
induced MOPr desensitization was completely reversed (Fig. 3F). The
MOPr desensitization induced by chronic in vivo morphine treatment
was homologous in that responses to sub-maximal and maximal
concentrations of NA were unaffected (Fig. 3G).
PKC is not involved in the MOPr desensitization following
prolonged in vitro exposure to DAMGO
To examine the MOPr desensitization induced by DAMGO, we used
two concentrations of the drug, 30 nm and 10 lm. DAMGO (30 nm)
is a sub-maximal concentration of the drug, being an approximate
Fig. 3. Maintenance of MOPr desensitization during prolonged morphine exposure in vitro and in vivo requires ongoing PKC activation. (A) Sample current trace
from an LC neuron pre-incubated with 30 lm morphine (morph) for > 6 h, followed by 30 lm morphine + 1 lm Go6976 for 30–50 min. Note that the morphine
response was elevated compared with Fig. 1D. Scale bars: 50 pA and 5 min. (B) Pooled data from experiments as shown in (A). The decrease in morphine response
following pre-incubation with 1 lm morphine and 10 lm oxo-tremorine-M (oxo-M) for 6–9 h was reversed by the addition of the PKC inhibitor, Go6976 (1 lm) for
the ﬁnal 30–50 min of pre-incubation. Similarly, the decreased morphine response following 6–9 h pre-incubation with 30 lm morphine was reversed by Go6976
(1 lm) applied during the ﬁnal 30–50 min of pre-incubation (*P < 0.05 vs. control;
P < 0.05 vs. 1 lm morphine + oxo-M;
P < 0.05 vs. 30 lm morphine,
Student’s t-test; n = 3–6). (C) Pre-incubation with 30 lm morphine for 6–9 h resulted in a signiﬁcant loss of MOPr responsiveness, as seen in Fig. 1E. This effect
was completely reversed when all of the conventional PKC isoforms were inhibited for the ﬁnal 30–50 min of pre-incubation by application of 1 lm of the RACK
inhibitor of all conventional PKC isoforms. When 1 lm each of the bI, bII and c isoforms RACK inhibitors were co-applied, loss of MOPr responsiveness was
unaffected (n = 3–6). All error bars represent SEM (*P < 0.05 vs. control pre-incubation;
P < 0.05 vs. 6–9 h 30 lm morphine pre-incubation). (D) Pooled data
from experiments on slices taken from animals pre-treated with morphine for 3 days. Slices from morphine-pre-treated animals were maintained in morphine 1 lm to
prevent them going into withdrawal. In these slices the maximum response (i.e. to morphine 30 lm) was signiﬁcantly decreased compared with that observed in
parallel experiments on LC neurons from non-morphine-treated animals. This decrease was signiﬁcantly reversed by inclusion of Go6976 (1 lm) for the ﬁnal 30 min
before determining the maximum response to morphine. n = 4–6, error bars represent SEM (*P < 0.05 vs. control;
P < 0.05 vs. chronic morphine). (E) MOPr
desensitization in slices taken from morphine-pre-treated animals is reversed if slices are maintained for 2–4 h after slicing in morphine-free bathing solution. n =
3–5, error bars represent SEM (*P < 0.05 vs. control;
P < 0.05 vs. chronic morphine, morphine in bathing solution). (F) MOPr desensitization caused by in vivo
morphine treatment is homologous. In control slices, similar responses are obtained following 30 lm morphine or 1 lm nociception. In slices taken from morphine-
pre-treated animals, the nociception response is unchanged, whereas the morphine response is signiﬁcantly reduced. n = 3–5, error bars represent SEM (*P < 0.05
vs. control animals). (G) Responses to sub-maximal and maximal concentrations of NA in slices taken from morphine-pre-treated animals (open circles) were not
different to those observed in slices taken from control animals (black squares; n = 5; error bars represent SEM).
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response to 30 lm morphine), whereas 10 lm DAMGO is a receptor-
saturating concentration. Both concentrations of DAMGO induced
profound rapid MOPr desensitization (Fig. 4A–C). By applying
morphine (30 lm) immediately following exposure to DAMGO we
could again measure the extent of MOPr desensitization by the
decrease in the maximum response to morphine. Acute (10 min)
exposure to DAMGO 30 nm and 10 lm both produced marked
decreases in the maximum response to morphine (Fig. 4B). Rapid
MOPr desensitization by DAMGO was unaffected by the PKC
inhibitor Go6976 (1 lm; Fig. 4C).
MOPr desensitization persisted after prolonged (6–9 h) exposure to
DAMGO 30 nm or 10 lm (Fig. 4D and E). Incubation of the slices
with Go6976 (1 lm) for the last 30–50 min of DAMGO pre-
incubation did not inhibit the MOPr desensitization induced by either
concentration of DAMGO (Fig. 4E ). Therefore, MOPr desensitization
induced by prolonged DAMGO exposure was not mediated by PKC.
Loss of receptor function underlying MOPr desensitization
by different agonists
We have used the operational model of agonism [Eq. (1) above; Black
et al., 1985; ] to determine the actual loss of MOPr function that is
responsible for the levels of desensitization observed. This is
important because the actual loss of receptor function required to
reduce the maximum response to a full agonist may be much greater
than that required to cause a similar reduction in the maximum
response to a partial agonist as a full agonist will have a receptor
reserve that must be removed before any loss of maximum response is
observed (Connor et al., 2004).
Fig. 4. MOPr desensitization induced by DAMGO is PKC independent. (A) Sample current recording showing a 10-min application of DAMGO (30 nm) followed
by administration of morphine (morph; 30 lm), 10 lm DAMGO, naloxone (nalox; 1 lm) and noradrenaline (NA; 100 lm) to obtain the maximum opioid and NA
responses. Scale bars: 50 pA and 5 min. (B) Pooled data from experiments as shown in (A). DAMGO applied for 10 min at 30 nm or 10 lm caused rapid MOPr
desensitization (*P < 0.05 vs. control, Student’s t-test; n = 3–6). (C) The acute desensitization of the DAMGO-induced response (shown as a percentage of initial
peak response) during an 8-min application of 10 lm DAMGO (open circles) was unaffected by inhibition of PKC with 1 lm Go6976 (black squares). (D) Sample
current recording following 6–9 h pre-treatment in vitro with 10 lm DAMGO and DAMGO + Go6976 for the last 30–50 min followed by morphine (morph;
30 lm), naloxone (nalox; 1 lm) and noradrenaline (NA; 100 lm) to ﬁnd the maximum morphine and NA responses. (E) Pooled data from experiments as shown in
(D). MOPr desensitization caused by prolonged (6–9 h) DAMGO pre-incubation was not reversed by inhibition of PKC with 1 lm Go6976 (n = 3–6; error bars
represent SEM).
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in control and in neurons pre-treated with the irreversible MOPr
antagonist b-FNA, with the lines of best-ﬁt derived from the
operational model of agonism. In LC neurons, the values for MOPr
activation are: Em (theoretical maximum response) = 115%; n (slope
of the curve; NB not the Hill slope) = 0.96. For morphine (see
Fig. 5. Converting empirical data of morphine responses to loss of receptor function: morphine-induced profound loss of receptor function. (A) Concentration–
response curves constructed from the responses to Met-Enkephalin in the absence (squares) and presence (triangles) of the irreversible MOPr antagonist b-FNA,
applied at 30 nm for 30 min. Lines of best-ﬁt were obtained following simultaneous linear-regression analysis using the operational model of agonism. (B) Under
conditions resulting in loss of receptor function, s would be decreased, resulting in a decrease in the response elicited by 30 lm morphine (% morphine max).
Empirical data (response to 30 lm morphine following loss of functional receptor normalized to response to 30 lm morphine under control conditions, i.e. %
maximum morphine response) could thus be converted to % loss of receptor function. (C) Met-Enkephalin (Met-Enk; 30 lm) for 10 min resulted in rapid MOPr
desensitization. The response to morphine in this desensitized state was 13.7 ± 5.3% that of control (n =4 ;* P < 0.05 vs. control; D), this corresponds to a 95 ± 2%
loss of receptor function (E). (F) Empirical data shown in Figs 1 and 4 converted to % loss of receptor function. Black circles, 10 lm DAMGO; black squares, 30 nm
DAMGO; open circles, 30 lm morphine. Each point represents mean empirical data converted to % loss of receptor function. (G) Empirical data shown in Fig. 2
converted to percentage loss of receptor function.
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constant) = 1.6 lm and s (the transducer ratio) = 1.60. These values
are similar to those reported by Osborne & Williams (1995) for MOPr
activation in LC neurons.
This then enables us to derive a model (Fig. 5B) whereby the
functional change in the amplitude of the response to morphine
(30 lm) resulting from MOPr desensitization (x-axis, Fig. 5B) can
then be used to calculate new values for s and, using Eq. (2), thus
calculate the actual loss of MOPr function (y-axis, Fig. 5B; see
Materials and methods for details and deﬁnitions). The percentage loss
of receptor function ( f ) is given by:
f ¼ 100  ð 1   s2=sÞ: ð2Þ
For example, the MOPr desensitization induced by acute exposure
to Met-Enkephalin (30 lm; Fig. 5C and D) reduced the response to
30 lm morphine to 14 ± 5% of control (n = 4; Fig. 5E). Using the
methods described above we calculated that this translated to a 95%
loss of MOPr function, a ﬁnding that corresponds well to a previous
estimate by Osborne & Williams (1995). We have then gone on to
convert the empirical data in Figs 1–4 to % loss of MOPr function.
Acute exposure of neurons to DAMGO very rapidly induced a high
loss of MOPr function, such that after only a 10-min exposure to
30 nm DAMGO or 1 lm DAMGO there was a 79% and 98% loss of
MOPr function, respectively (Fig. 5F). The loss of MOPr function
induced by acute morphine was less, even in the presence of PKC
activation. Thus, a 7-min exposure to morphine (1 lm) in the absence
or presence of PMA induced no loss of MOPr function (see Fig. 2C),
whereas over the same time period 30 lm morphine in the presence of
PMA reduced MOPr function by 53%.
.
Treatment for 6–9 h with 1 lm morphine alone caused no
signiﬁcant decrease in MOPr function; however, when neurons were
incubated with 1 lm morphine and either oxo-M (10 lm) or PMA
(1 lm), receptor function was decreased by 70% and 74%, respec-
tively (Fig. 5G). Prolonged in vitro exposure to 30 lm morphine alone
did cause profound loss of MOPr function (Fig. 5F), but this occurred
more slowly than with DAMGO. Following 6–9 h treatment with
30 lm morphine, there was an 82% loss of MOPr function, which
compares to that induced by acute (10 min) DAMGO. In neurons
from animals pre-treated with morphine, MOPr receptor function was
decreased by 71%, which is the same as that observed with in vitro
morphine plus PMA or oxo-M treatment.
It appears therefore that exposure to DAMGO induces MOPr
desensitization that is both rapid in onset and extensive, whereas
morphine-induced MOPr desensitization develops more slowly,
requires ongoing PKC activation, but both in vitro and in vivo
morphine treatment can induce a similar level of loss of receptor
function.
Discussion
A central ﬁnding of this study is that prolonged exposure of mature
neurons to morphine causes profound MOPr desensitization. It had
been suggested that morphine produces tolerance because it does not
induce rapid MOPr desensitization and that morphine tolerance occurs
following subsequent, as yet unknown, adaptive changes caused by
prolonged MOPr signalling (Finn & Whistler, 2001). Our data would
refute that hypothesis. Morphine does induce homologous MOPr
desensitization, following prolonged in vitro or in vivo morphine
treatment. This ﬁnding re-conﬁrms the view that MOPr desensitization
contributes to morphine tolerance.
To circumvent problems in the interpretation of opioid agonist-
induced desensitization data (reviewed in Connor et al., 2004), we
speciﬁcally designed our experiments so that we could investigate
agonist coupling and desensitization immediately following long-term
in vitro or in vivo morphine treatments, in the absence of complica-
tions due to drug withdrawal. Indeed, after 2–4 h morphine with-
drawal in vitro, MOPr desensitization was reversed. This suggests that
the MOPr desensitization we observed was somewhat transient, in
contrast with that seen by Christie et al. (1987) where MOPr
desensitization was still seen in rat LC neurons up to 6 h after
morphine withdrawal in vitro. In that study the chronic morphine
treatment used higher doses than in this study (> 2700 mg⁄kg
morphine pellets over 7 days vs 200 mg⁄kg emulsion over 3 days),
and possibly in their experiments the level of chronic treatment
induced additional adaptive mechanisms, such as enhanced GRK and
arrestin activity (Terwilliger et al., 1994) or receptor downregulation
that may result in longer-lasting MOPr desensitization.
Further, there have been recent studies in LC and periaqueductal
grey neurons demonstrating that, following in vitro withdrawal from
chronic morphine treatment, MOPrs exhibit enhanced agonist-induced
desensitization (Dang & Williams, 2005; Ingram et al., 2008). These
studies suggest the possibility that morphine withdrawal and⁄or higher
levels of morphine tolerance may induce additional adaptive mech-
anisms, such as effects on GRKs or RGS proteins (Terwilliger et al.,
1994; Gold et al., 2003).
Our data with PKC inhibitors reversing morphine-induced desen-
sitization appear somewhat at odds with those of Dang & Williams,
2005. In their paper, using sharp electrode recording, they observed
that a relatively high concentration of chelerythrine enhanced the
desensitization induced by morphine-6-glucuronide. We have shown
in this paper and previously (Bailey et al., 2004) that a range of
structurally different PKC inhibitors reverse morphine-induced desen-
sitization.
To obtain a quantitative measure of functional MOPr loss, we
subjected the data to operational analysis (Black et al., 1985) to obtain
a quantitative measure of functional MOPr loss. This revealed that
prolonged exposure to morphine both in vitro and in vivo resulted in
up to an 82% loss in MOPr function (Christie et al., 1987). Although
the desensitization induced by morphine was slightly less than that
induced by DAMGO and developed over a longer time period, it is
evident that prolonged morphine exposure can induce robust loss of
MOPr function in adult mammalian neurons. Importantly, MOPr
desensitization occurs at the level of the MOPr and not downstream
of the receptor, as the NA-induced K
+-current in the same neurons
was unaffected. a2-Adrenoceptors and MOPrs couple to the same set
of K
+ channels in LC neurons (North & Williams, 1985).
Inhibitors of PKC signiﬁcantly reversed MOPr desensitization even
after the desensitization had been allowed to develop (over 3 days of
morphine treatment in vivo and 6–9 h morphine treatment in vitro).
This shows that for morphine desensitization to persist, ongoing PKC
activity is required. Crucially, this ﬁnding is paralleled in previous
studies of morphine analgesia tolerance in vivo where PKC inhibitors
were able to reverse tolerance even when they were ﬁrst administered
after 3 days of morphine exposure (Smith et al., 1999). Furthermore,
in vivo morphine analgesia tolerance can be potentiated by a PP2A
phosphatase inhibitor, indicating that the level of tolerance is
dependent upon the balance between ongoing MOPr phosphorylation
and dephosphorylation by PP2A (Gabra et al., 2007).
PKC exists as multiple isoforms (Way et al., 2000), many of which
are expressed in CNS neurons. In LC neurons a single conventional
PKC isoform, PKCa, appears to be responsible for the PKC
component of morphine-induced MOPr desensitization. However,
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induced MOPr desensitization, and it is entirely possible that in
different neuronal populations other isoforms of PKC may be
involved. Indeed, in vivo, there is evidence from analgesia studies
that morphine tolerance may involve not only PKCa but also PKCe
and PKCc (Zeitz et al., 2001; Hua et al., 2002; Newton et al., 2007;
Smith et al., 2007).
In LC neurons DAMGO induces rapid (t1 ⁄ 2 = 150 s) MOPr
desensitization (Harris & Williams, 1991; Bailey et al., 2003). We
have reported that in HEK-293 cells rapid DAMGO-induced MOPr
desensitization is GRK-mediated because it is blocked by over-
expression of a GRK2 dominant negative mutant (Johnson et al.,
2006). In the present experiments we sought to determine whether, on
prolonged exposure to DAMGO, a PKC component of MOPr
desensitization was revealed. This does not appear to be the case
because treatment with a PKC inhibitor that blocked morphine-
induced MOPr desensitization failed to alter the DAMGO-induced
desensitization following 6–9 h pre-treatment with DAMGO. Fur-
thermore, it might have been expected that DAMGO would induce
less MOPr desensitization than morphine given that DAMGO induces
not only MOPr desensitization but also MOPr internalization that
would result in MOPr resensitization by dephosphorylation and then
re-insertion of reactivated receptors into the plasma membrane,
whereas morphine induces much less MOPr internalization. However,
we found that a receptor-saturating concentration of DAMGO induced
an almost complete loss of MOPr function.
In LC neurons in vitro under conditions of low PKC activity, a
component of morphine-induced rapid MOPr desensitization persists
(Bailey et al., 2004; Dang & Williams, 2005; Virk & Williams, 2008).
This could be because there is, in addition to PKC-mediated
desensitization, a component of morphine desensitization that is
GRK-mediated. This might also explain why, in our ex vivo experi-
ments where neurons had been exposed to morphine for 3 days, the
PKC inhibitor did not completely reverse MOPr desensitization, and
why a small, but signiﬁcant amount of receptor internalization was
induced by morphine in HEK-293 cells (Johnson et al., 2006) and
striatal neurons (Haberstock-Debic et al., 2005).
The present results, together with our previous work (Bailey et al.,
2004; Johnson et al., 2006), reveal that there are four main factors that
determine the development of MOPr desensitization: the nature of the
agonist ligand; the degree of receptor occupancy; the duration of
morphine treatment; and the level of PKC activation. LC neurons in
the slice preparation can be considered to be in a ‘basal state’, where
PKC activity is lower than in the same neurons in vivo,a sin vivo
ongoing synaptic activity will activate Gq-coupled metabotropic
receptors and Ca
2+-permeable ionotropic receptors that would elevate
PKC activity. Prolonged exposure to a sub-maximal, therapeutically
relevant concentration of morphine (1 lm) induced MOPr desensiti-
zation in vitro only when PKC activity was elevated. In contrast, when
slices were prepared from morphine-pre-treated rats and maintained in
this concentration of morphine, profound MOPr desensitization was
observed that could be reversed by inhibiting PKC. Comparable levels
of MOPr desensitization in the brain have been reported using agonist-
induced [
35S]GTPcS autoradiography following chronic morphine
administration to rats, although the molecular mechanism of desen-
sitization was not identiﬁed (Sim et al., 1996).
There is now also good evidence to indicate that endogenous levels
of PKC play a major role in morphine tolerance in vivo. Tolerance
to the antinociceptive effects of morphine can be reduced by
co-administration of PKC inhibitors (Granados-Soto et al., 2000;
Inoue & Ueda, 2000; Bohn et al., 2002; Hua et al., 2002; Smith et al.,
2003) or by blockade of various Gq-coupled receptors (Watkins et al.,
1984; Dourish et al., 1990; Mitchell et al., 2000; Popik et al., 2000;
Powell et al., 2000, 2003; Tortorici et al., 2003). What our in vitro and
ex vivo experiments on brain slices demonstrate is that the site of action
of PKC is within the MOPr-expressing neurons themselves, and that
PKC activation enhances morphine-induced MOPr desensitization.
In conclusion, we show that morphine can induce robust desensi-
tization of endogenously expressed MOPrs in mature neurons both
in vitro and in vivo, and that this desensitization requires ongoing
activation of PKC. Our data support the view that MOPr desensiti-
zation by a PKC-dependent mechanism underlies the maintenance of
morphine tolerance.
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